DuPont Appoints DuPont Pharmaceuticals Leadership

DuPont this week appointed two veteran pharmaceutical industry executives to lead DuPont Pharmaceuticals once the DuPont Merck Pharmaceutical Company joint venture is completed.

Nicholas Teti, currently president of the pharmaceuticals division of DuPont Merck, will be appointed president of DuPont Pharmaceuticals.

Dr. Paul A. Friedman, currently president of the DuPont Merck Research Labs, will be appointed president of DuPont Pharmaceuticals Research Laboratories.

As president of the DuPont Merck pharmaceuticals division, Teti has restructured worldwide business operations, created a European business focused on five key countries, and positioned the business to pursue business opportunities in Latin America.

Friedman is a diplomat of the American Board of Internal Medicine, a recipient of the James Talbot Shipley Prize for Research at Harvard Medical School, and a former member and chairman of the National Institutes of Health Biochemistry Study Section.

Some of DuPont Merck's best-known commercial drugs are Coumadin, an oral anticoagulant; Sinemet, a treatment for Parkinson's disease; ReVia, a treatment for alcohol dependency and Cardiolite, a heart-imaging agent.

For more information contact: Roger Morris, DuPont, Tel: 302-992-4747